Immuneering
IMRX
85 hedge funds and large institutions have $209M invested in Immuneering in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 14 closing their positions.
183% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $828K
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25% more funds holding
Funds holding: 68 → 85 (+17)
14% more capital invested
Capital invested by funds: $182M → $209M (+$26.3M)
13.53% less ownership
Funds ownership: 62.65% → 49.11% (-14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$14.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.77M |
| 3 |
BlackRock
New York
|
+$4.95M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$2.83M |
| 5 |
Goldman Sachs
New York
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$10.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.65M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.47M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.1M |
| 5 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$1.93M |
IMRX Hedge Fund Activity: Q4 2025 in Review
85 of the 8,278 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2025, worth a combined $209M — up 14% from $182M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new IMRX positions and 14 closed out — a net gain of 17 holders — while 27 added to existing stakes and 11 trimmed.
The largest buyer was State Street, adding an estimated $14.3M. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $10.6M sold.
- 85 institutional investors held Immuneering (IMRX) as of Q4 2025, up from 68 in Q3 2025.
- Funds reported $209M of Immuneering stock for Q4 2025, up 14% quarter-over-quarter.
- 31 funds opened new Immuneering positions in Q4 2025 and 14 closed out, a net change of +17 holders.
- The largest Immuneering buyer in Q4 2025 was State Street, an estimated $14.3M added.
- The largest Immuneering seller in Q4 2025 was ExodusPoint Capital Management, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2025.